BRPI0818680A2 - composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica - Google Patents

composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica

Info

Publication number: BRPI0818680A2
Authority: BR; Brazil
Prior art keywords: pharmaceutical; preparing; dosage form; oral; preparation
Prior art date: 2007-10-26

Application number

BRPI0818680A

Other languages

English (en)

Inventor

Jorge Dos Santos Lima Ricardo

Cerdeira De Campos Costa Rui

Cardoso De Vasconcelos Teófilo

Original Assignee

Bial - Portela & Cia S A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-26

Filing date

2008-10-24

Publication date

2017-05-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40254311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818680(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-10-24 Application filed by Bial - Portela & Cia S A filed Critical Bial - Portela & Cia S A

2017-05-02 Publication of BRPI0818680A2 publication Critical patent/BRPI0818680A2/pt

2022-05-24 Publication of BRPI0818680B1 publication Critical patent/BRPI0818680B1/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Zoology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0818680-4A 2007-10-26 2008-10-24 Comprimido ou cápsula compreendendo acetato de licarbazepina BRPI0818680B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US98279007P	2007-10-26	2007-10-26
US60/982790		2007-10-26
PCT/PT2008/000043 WO2009054743A1 (en)	2007-10-26	2008-10-24	Oral dosage forms comprising licarbazξpine acetate

Publications (2)

Publication Number	Publication Date
BRPI0818680A2 true BRPI0818680A2 (pt)	2017-05-02
BRPI0818680B1 BRPI0818680B1 (pt)	2022-05-24

Family

ID=40254311

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0818680-4A BRPI0818680B1 (pt)	2007-10-26	2008-10-24	Comprimido ou cápsula compreendendo acetato de licarbazepina

Country Status (24)

Country	Link
US (5)	US8372431B2 (pt)
EP (2)	EP3202392B1 (pt)
JP (4)	JP2011500797A (pt)
KR (3)	KR20170004034A (pt)
CN (1)	CN101848698A (pt)
AR (1)	AR069031A1 (pt)
AU (1)	AU2008317584B2 (pt)
BR (1)	BRPI0818680B1 (pt)
CA (1)	CA2703313C (pt)
CY (1)	CY1118350T1 (pt)
DK (1)	DK2214636T3 (pt)
ES (2)	ES2898202T3 (pt)
HR (1)	HRP20161329T1 (pt)
HU (1)	HUE030788T2 (pt)
IL (1)	IL205160A0 (pt)
LT (1)	LT2214636T (pt)
MX (1)	MX2010004323A (pt)
PL (1)	PL2214636T3 (pt)
PT (2)	PT3202392T (pt)
RS (1)	RS55376B1 (pt)
RU (1)	RU2546521C2 (pt)
SI (1)	SI2214636T1 (pt)
UA (1)	UA110012C2 (pt)
WO (1)	WO2009054743A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060252745A1 (en)	2005-05-06	2006-11-09	Almeida Jose L D	Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en)	2007-01-15	2007-02-21	Portela & Ca Sa	Drug therapies
US8372431B2 (en)	2007-10-26	2013-02-12	Bial-Portela & C.A., S.A.	Pharmaceutical composition comprising licarbazepine acetate
KR20140016438A (ko)	2009-07-21	2014-02-07	케릭스 바이오파마슈티컬스 인코포레이티드	구연산철 투여형태
RU2012106827A (ru)	2009-07-27	2013-09-10	БИАЛ-ПОРТЕЛА энд КА., С.А.	Применение производных 5н-дибенз/в, f/азепин-5-карбоксамида для лечения фибромиалгии
AU2010313571B2 (en)	2009-10-26	2014-07-31	Merck Sharp & Dohme Llc	Solid pharmaceutical compositions containing an integrase inhibitor
US20120121703A1 (en) *	2010-07-20	2012-05-17	Japan Tobacco Inc.	Tablet containing ferric citrate
TR201008460A1 (tr)	2010-10-15	2012-05-21	Sanovel İlaç San.Ve Ti̇c.A.Ş.	Eslikarbazepinin saşe formülasyonları.
MX350531B (es)	2010-12-31	2017-09-08	BIAL PORTELA & Cª S A	Granulados que comprenden acetato de eslicarbazepina.
US9750747B2 (en)	2011-08-26	2017-09-05	Bail-Portela & Ca, S.A.	Treatments involving eslicarbazepine acetate or eslicarbazepine
EP3103444A1 (en)	2015-06-09	2016-12-14	Sanovel Ilac Sanayi ve Ticaret A.S.	Pharmaceutical compositions of lacosamide and eslicarbazepine
EP3402488B1 (en) *	2015-12-18	2021-10-27	Jubilant Generics Limited	Solid oral dosage forms of eslicarbazepine
WO2018004391A1 (ru) *	2016-06-29	2018-01-04	Общество С Ограниченной Ответственностью "Валента-Интеллект"	Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
CN106913550B (zh) *	2017-03-10	2019-12-17	扬子江药业集团北京海燕药业有限公司	一种醋酸艾司利卡西平片的制备方法
WO2019058354A1 (en) *	2017-09-25	2019-03-28	Jubilant Generics Limited	SUSPENSION OF ESLICARBAZÉPINE
US11318145B2 (en)	2018-09-25	2022-05-03	Jubilant Generics Limited	Eslicarbazepine suspension
EA037195B1 (ru) *	2018-03-28	2021-02-18	Акционерное Общество "Химфарм"	Биологически активная добавка для улучшения функционального состояния дыхательной системы и восстановления иммунной системы (варианты)
JPWO2020054647A1 (ja)	2018-09-14	2021-11-11	学校法人慶應義塾	アストロサイトの製造方法
HUP1900153A1 (hu)	2019-05-14	2020-11-30	Meditop Gyogyszeripari Kft	Eszlikarbazepin-acetát tartalmú granulátum, ennek elõállítása, ezt tartalmazó egyéb gyógyszerkészítmények, és ezek alkalmazása
WO2021226256A1 (en) *	2020-05-05	2021-11-11	Neurobo Pharmaceuticals, Inc.	Niclosamide formulations and methods of use

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5326570A (en) *	1991-07-23	1994-07-05	Pharmavene, Inc.	Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
ZA953078B (en)	1994-04-28	1996-01-05	Alza Corp	Effective therapy for epilepsies
PT101732B (pt) *	1995-06-30	1997-12-31	Portela & Ca Sa	Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
US6296873B1 (en) *	1997-01-23	2001-10-02	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es)	1997-02-14	2000-05-29	Novartis Ag	Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
GB9721497D0 (en) *	1997-10-09	1997-12-10	Ciba Geigy Ag	Organic compounds
PL197989B1 (pl) *	1997-12-19	2008-05-30	Smithkline Beecham Corp	Sposób wytwarzania szybko rozpraszających się tabletek do podawania doustnego, szybko rozpraszający się preparat farmaceutyczny w postaci tabletek i szybko rozpraszająca się, farmaceutycznie dopuszczalna, tabletka do podawania doustnego
SA99191255B1 (ar)	1998-11-30	2006-11-25	جي دي سيرل اند كو	مركبات سيليكوكسيب celecoxib
UA74141C2 (uk) *	1998-12-09	2005-11-15	Дж.Д. Сірл Енд Ко.	Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
IN190699B (pt) *	2001-02-02	2003-08-16	Sun Pharmaceutical Ind Ltd
GB0111566D0 (en) *	2001-05-11	2001-07-04	Portela & Ca Sa	Method for preparation of (s)-(+)-and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azephine-5-carboxamide
GB0112812D0 (en) *	2001-05-25	2001-07-18	Portela & Ca Sa	Mthd for preparation of 10, 11-dihydro-10-hydroxy-5H-dibenz/B,F/azepine-5-c arboxamide and 10,11-dihydro-10-oxo-5H-dibenz/B,F/azepine-5-carb oxamide therefrom
WO2003075830A2 (en) *	2002-03-14	2003-09-18	Sun Pharmaceutical Industries Limited	Oral controlled drug delivery system containing carbamazepine
JP2005528429A (ja) *	2002-05-31	2005-09-22	デジティンアーツナイミッテルゲーエムベーハー	活性成分の徐放性を有するオクスカルバゼピン含有薬学的組成物
DE10224170A1 (de) *	2002-05-31	2003-12-11	Desitin Arzneimittel Gmbh	Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
DE10230027A1 (de)	2002-07-04	2004-01-22	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Arzneimittelkombinationen auf der Basis von Natriumkanalblockern und Magnesiumsalzen
GB0221956D0 (en)	2002-09-20	2002-10-30	Novartis Ag	Organic compounds
JP2006509735A (ja)	2002-10-17	2006-03-23	ノバルティスアクチエンゲゼルシャフト	オクスカルバゼピンまたはその誘導体およびｃｏｘ２インヒビターからなる疼痛処置用医薬組成物
US20040087642A1 (en) *	2002-10-24	2004-05-06	Zeldis Jerome B.	Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
GB2401605A (en) *	2003-05-12	2004-11-17	Portela & Ca Sa	Method for racemisation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and optically enriched mixtures thereof
US20070196396A1 (en) *	2004-02-11	2007-08-23	Rubicon Research Private Limited	Controlled release pharmaceutical compositions with improved bioavailability
WO2005090418A1 (en)	2004-03-17	2005-09-29	Dsm Ip Assets B.V.	Polimerization catalyst comprising an amidine ligand
AR048672A1 (es)	2004-03-22	2006-05-17	Novartis Ag	Tabletas de desintegracion que comprenden licarbazepina
AR048318A1 (es)	2004-03-22	2006-04-19	Novartis Ag	Formulaciones de matriz orales que comprenden licarbazepina
GB2416167A (en)	2004-07-13	2006-01-18	Portela & Ca Sa	Chiral inversion and esterification of (S)- and (R)-10-hydroxy-dibenzazepine carboxamides
EP1787642A1 (en)	2004-11-10	2007-05-23	Teva Pharmaceutical Industries Ltd.	Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
GB0425320D0 (en) *	2004-11-17	2004-12-22	Johnson Matthey Plc	Diamines
GB2422149A (en) *	2005-01-14	2006-07-19	Portela & Ca Sa	Process for the preparation of 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide
US20060252745A1 (en) *	2005-05-06	2006-11-09	Almeida Jose L D	Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
MX2007013882A (es)	2005-05-06	2008-01-28	Portela & Ca Sa	Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.
EP2380573B1 (en)	2005-05-06	2015-02-25	Bial-Portela & CA, S.A.	Eslicarbazepine acetate and methods of use
US8059672B2 (en)	2005-05-18	2011-11-15	Sprint Communications Company L.P.	Internet communications between wireless base stations and service nodes
US20070071819A1 (en) *	2005-05-30	2007-03-29	Kesarwani Amit K	Multiple unit modified release compositions of carbamazepine and process for their preparation
US20090143360A1 (en)	2005-07-08	2009-06-04	Muhammed Safadi	Oxcarbazepine Formulation
GB0515690D0 (en)	2005-07-29	2005-09-07	Portela & Ca Sa	Asymmetric catalytic reduction
WO2007029093A2 (en)	2005-09-05	2007-03-15	Ranbaxy Laboratories Limited	Pharmaceutical dosage forms of oxcarbazepine
JP2008538783A (ja)	2006-01-31	2008-11-06	テバファーマシューティカルインダストリーズリミティド	ブロード且つ多峰性の粒度分布を有するオキシカルバゼピンを含む医薬製剤及びその調製方法
JP2008540346A (ja)	2006-01-31	2008-11-20	テバファーマシューティカルインダストリーズリミティド	オキシカルバゼピンの医薬製剤及びその調製方法
GB0603008D0 (en)	2006-02-14	2006-03-29	Portela & Ca Sa	Method
GB2437078A (en)	2006-04-11	2007-10-17	Portela & Ca Sa	10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives
EP2077822B1 (en)	2006-09-27	2018-04-25	Medley S.A. Indústria Farmacêutica	Oxcarbazepine-containing oral formulation and a process to obtain the same
US20080138403A1 (en)	2006-12-08	2008-06-12	Sun Pharmaceutical Industries Ltd.	Pharmaceutical dosage forms of oxcarbazepine
US8372431B2 (en)	2007-10-26	2013-02-12	Bial-Portela & C.A., S.A.	Pharmaceutical composition comprising licarbazepine acetate
EP3402488B1 (en)	2015-12-18	2021-10-27	Jubilant Generics Limited	Solid oral dosage forms of eslicarbazepine

2008
- 2008-10-23 US US12/257,240 patent/US8372431B2/en active Active
- 2008-10-24 ES ES16180687T patent/ES2898202T3/es active Active
- 2008-10-24 KR KR1020167036806A patent/KR20170004034A/ko active Search and Examination
- 2008-10-24 RU RU2010121135/15A patent/RU2546521C2/ru active
- 2008-10-24 RS RS20160895A patent/RS55376B1/sr unknown
- 2008-10-24 DK DK08842368.6T patent/DK2214636T3/en active
- 2008-10-24 HU HUE08842368A patent/HUE030788T2/en unknown
- 2008-10-24 BR BRPI0818680-4A patent/BRPI0818680B1/pt not_active IP Right Cessation
- 2008-10-24 PT PT161806872T patent/PT3202392T/pt unknown
- 2008-10-24 JP JP2010530951A patent/JP2011500797A/ja active Pending
- 2008-10-24 KR KR1020187037643A patent/KR102116087B1/ko active IP Right Grant
- 2008-10-24 PL PL08842368T patent/PL2214636T3/pl unknown
- 2008-10-24 PT PT88423686T patent/PT2214636T/pt unknown
- 2008-10-24 WO PCT/PT2008/000043 patent/WO2009054743A1/en active Application Filing
- 2008-10-24 EP EP16180687.2A patent/EP3202392B1/en active Active
- 2008-10-24 CN CN200880112983A patent/CN101848698A/zh active Pending
- 2008-10-24 UA UAA201006417A patent/UA110012C2/ru unknown
- 2008-10-24 AR ARP080104652A patent/AR069031A1/es unknown
- 2008-10-24 MX MX2010004323A patent/MX2010004323A/es active IP Right Grant
- 2008-10-24 SI SI200831687A patent/SI2214636T1/sl unknown
- 2008-10-24 EP EP08842368.6A patent/EP2214636B1/en active Active
- 2008-10-24 AU AU2008317584A patent/AU2008317584B2/en active Active
- 2008-10-24 ES ES08842368.6T patent/ES2607002T3/es active Active
- 2008-10-24 KR KR1020107011233A patent/KR20100093057A/ko active Application Filing
- 2008-10-24 LT LTEP08842368.6T patent/LT2214636T/lt unknown
- 2008-10-24 CA CA2703313A patent/CA2703313C/en active Active
2010
- 2010-04-18 IL IL205160A patent/IL205160A0/en unknown
2013
- 2013-01-30 US US13/754,439 patent/US20130150348A1/en not_active Abandoned
- 2013-12-17 US US14/108,615 patent/US9566244B2/en active Active
2014
- 2014-07-10 JP JP2014141894A patent/JP6043758B2/ja not_active Expired - Fee Related
2016
- 2016-07-27 JP JP2016147183A patent/JP2017014233A/ja active Pending
- 2016-10-12 HR HRP20161329TT patent/HRP20161329T1/hr unknown
- 2016-12-14 CY CY20161101294T patent/CY1118350T1/el unknown
2017
- 2017-01-04 US US15/397,945 patent/US10912781B2/en active Active
2018
- 2018-06-26 JP JP2018120334A patent/JP2018172407A/ja active Pending
2021
- 2021-01-29 US US17/248,581 patent/US20210322436A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP3202392A1 (en)	2017-08-09
EP2214636B1 (en)	2016-09-28
BRPI0818680B1 (pt)	2022-05-24
CY1118350T1 (el)	2017-06-28
KR20100093057A (ko)	2010-08-24
EP3202392B1 (en)	2021-08-25
MX2010004323A (es)	2010-05-05
RU2010121135A (ru)	2011-12-10
DK2214636T3 (en)	2017-01-16
US20090110722A1 (en)	2009-04-30
US20210322436A1 (en)	2021-10-21
HRP20161329T1 (hr)	2016-12-02
IL205160A0 (en)	2010-11-30
AU2008317584B2 (en)	2015-01-22
PT3202392T (pt)	2021-11-23
HUE030788T2 (en)	2017-06-28
JP2014237658A (ja)	2014-12-18
ES2607002T3 (es)	2017-03-28
KR102116087B1 (ko)	2020-05-28
KR20170004034A (ko)	2017-01-10
LT2214636T (lt)	2016-11-25
US8372431B2 (en)	2013-02-12
CN101848698A (zh)	2010-09-29
CA2703313C (en)	2017-03-07
WO2009054743A1 (en)	2009-04-30
AU2008317584A1 (en)	2009-04-30
CA2703313A1 (en)	2009-04-30
JP2011500797A (ja)	2011-01-06
KR20190000929A (ko)	2019-01-03
JP2018172407A (ja)	2018-11-08
US10912781B2 (en)	2021-02-09
US20140343043A1 (en)	2014-11-20
US20130150348A1 (en)	2013-06-13
US20170112850A1 (en)	2017-04-27
PT2214636T (pt)	2016-12-20
JP2017014233A (ja)	2017-01-19
RS55376B1 (sr)	2017-03-31
US9566244B2 (en)	2017-02-14
PL2214636T3 (pl)	2017-02-28
RU2546521C2 (ru)	2015-04-10
SI2214636T1 (sl)	2017-01-31
AR069031A1 (es)	2009-12-23
ES2898202T3 (es)	2022-03-04
EP2214636A1 (en)	2010-08-11
UA110012C2 (uk)	2015-11-10
JP6043758B2 (ja)	2016-12-14

Publication	Publication Date	Title
BRPI0818680A2 (pt)	2017-05-02	composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica
BRPI0914918A2 (pt)	2015-10-20	forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida.
BRPI0905717A2 (pt)	2015-07-14	Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BRPI0819218A2 (pt)	2015-05-05	Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0814666A2 (pt)	2017-05-09	composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
BRPI0909691A2 (pt)	2015-08-04	Composto, método para preparar um composto, e, composição farmacêutica
BRPI0922174A2 (pt)	2015-12-29	preparação farmacêutica, uso de uma preparação, e, método para preparar uma preparação farmacêutica
BRPI0808034A2 (pt)	2014-06-17	Método para produzir hidrocloreto de prasugrel, hidrocloreto de prasugrel, composição farmacêutica, e, uso de um hidrocloreto de prasugrel.
BRPI0817917A2 (pt)	2015-04-07	Implemento para cuidado oral, e, método para formar um implemento para cuidado oral
BRPI1011764A2 (pt)	2016-03-29	composição farmacêutica, e, método para preparar uma composição farmacêutica
BRPI1007636A2 (pt)	2015-09-01	Composição farmacêutica, forma de dosagem, método para a preparação da composição farmacêutica, método de preparação da forma de dosagem e método de tratamento da dor
IL206159A0 (en)	2010-12-30	Oral pharmaceutical dosage forms
BRPI0813237A2 (pt)	2014-12-23	Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI1014865A2 (pt)	2016-05-03	"composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"
BR112012003280A2 (pt)	2017-05-23	composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
BRPI0922173A2 (pt)	2015-12-29	preparação farmacêutica, e, método para preparar uma preparação farmacêutica
BRPI1007484A2 (pt)	2016-02-16	composição farmacêutica para administração oral
BRPI0719880A2 (pt)	2014-06-10	Forma de dosagem sólida farmacêutica para administração oral e método para preparar a mesma.
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0905790A2 (pt)	2015-07-14	'micropartícula, método para a fabricação de micropartícula e preparação farmacêutica
BRPI1007161A2 (pt)	2016-02-23	composição farmacêutica oral, e processo para preparar uma composição
BRPI0918539A2 (pt)	2015-12-08	preparação farmacêutica sólida para administração oral
BRPI1007211A2 (pt)	2019-09-24	composição farmacêutica oral em uma forma sólida, e, processo para preparar uma composição.
IL213452A0 (en)	2011-07-31	Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
BRPI0812964A2 (pt)	2014-12-16	Forma de dosagem farmacêutica oral sólida

Legal Events

Date	Code	Title	Description
2018-03-06	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-03-27	B15K	Others concerning applications: alteration of classification	Ipc: A61K 31/55 (2006.01), A61K 9/00 (2006.01), A61K 9/
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2021-07-13	B350	Update of information on the portal [chapter 15.35 patent gazette]
2021-09-21	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-09-21	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2021-12-28	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2022-04-05	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2022-05-24	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/10/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.
2024-08-20	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 16A ANUIDADE.